|
Virus Diseases
|
0.030 |
AlteredExpression
|
group |
BEFREE |
The enzymatic activity and biological function of HDAC11 have been little known, but recent reports suggest that it has efficient defatty-acylation activity and that inhibiting it could be useful for treating a variety of human diseases, including viral infection, multiple sclerosis, and metabolic diseases.
|
31264832 |
2019 |
|
Virus Diseases
|
0.030 |
Biomarker
|
group |
BEFREE |
Therefore, our findings present exciting prospects for further investigations into significance of HDAC11 in virus infections.
|
30511515 |
2019 |
|
Diabetes Mellitus
|
0.030 |
Biomarker
|
group |
BEFREE |
These findings suggested that suppressing HDAC11 has therapeutic potential for treating diabetes mellitus-associated cardiac injury.
|
29655790 |
2018 |
|
Diabetes Mellitus
|
0.030 |
Biomarker
|
group |
BEFREE |
Overall, selective inhibition of HDAC11 could be a novel potential therapeutic avenue for both obesity and diabesity, the diabetes caused by obesity.
|
30126820 |
2018 |
|
Diabetes Mellitus
|
0.030 |
Biomarker
|
group |
BEFREE |
These findings define an epigenetic pathway for the regulation of energy homeostasis and suggest the potential for HDAC11-selective inhibitors for the treatment of obesity and diabetes.
|
30089714 |
2018 |
|
Obesity
|
0.030 |
Biomarker
|
disease |
BEFREE |
Overall, our findings distinguish HDAC11 as a novel regulator of obesity, with potentially important implications for obesity-related disease treatment.
|
29958910 |
2018 |
|
Obesity
|
0.030 |
Biomarker
|
disease |
BEFREE |
These findings define an epigenetic pathway for the regulation of energy homeostasis and suggest the potential for HDAC11-selective inhibitors for the treatment of obesity and diabetes.
|
30089714 |
2018 |
|
Obesity
|
0.030 |
Biomarker
|
disease |
BEFREE |
Overall, selective inhibition of HDAC11 could be a novel potential therapeutic avenue for both obesity and diabesity, the diabetes caused by obesity.
|
30126820 |
2018 |
|
Virus Diseases
|
0.030 |
Biomarker
|
group |
BEFREE |
Infectious Bronchitis Virus Infection Induces Apoptosis during Replication in Chicken Macrophage HD11 Cells.
|
28933760 |
2017 |
|
Chronic myeloproliferative disorder
|
0.020 |
Biomarker
|
disease |
BEFREE |
This work establishes HDAC11 as a unique type of target molecule having therapeutic potential in MPN.
|
31750881 |
2020 |
|
Salmonella infections
|
0.020 |
Biomarker
|
group |
BEFREE |
Since macrophages play an essential role in controlling Salmonella infection, the aim of this study was to evaluate the effect of glycyrrhizic acid (GA) on immune function of chicken HD11 macrophages.
|
30269446 |
2019 |
|
Liver carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Still, there was a strong correlation in the expression of HDAC class IIa (HDAC4, 5, 7, 9) as well as HDAC2 and 8 (class I) and HDAC10 (class IIb) and HDAC11 (class IV) in HCC tissues of individual patients.
|
31635225 |
2019 |
|
Autoimmune Diseases
|
0.020 |
Biomarker
|
group |
BEFREE |
Hence, antagonizing HDAC11 activity may have anti-tumor potential, whereas activating HDAC11 may be useful to treat chronic inflammation or autoimmunity.
|
29222071 |
2018 |
|
Diabetes
|
0.020 |
Biomarker
|
disease |
BEFREE |
Overall, selective inhibition of HDAC11 could be a novel potential therapeutic avenue for both obesity and diabesity, the diabetes caused by obesity.
|
30126820 |
2018 |
|
Diabetes
|
0.020 |
Biomarker
|
disease |
BEFREE |
These findings define an epigenetic pathway for the regulation of energy homeostasis and suggest the potential for HDAC11-selective inhibitors for the treatment of obesity and diabetes.
|
30089714 |
2018 |
|
Autoimmune Diseases
|
0.020 |
Biomarker
|
group |
BEFREE |
These data are powerful stimuli for the further development and testing of HDAC11-selective pharmacologic inhibitors, and may ultimately provide new therapies for transplantation and autoimmune diseases.
|
28819166 |
2017 |
|
Hodgkin Disease
|
0.020 |
Biomarker
|
disease |
BEFREE |
Patients and Methods We analyzed updated follow-up data on 4,276 patients treated within the German Hodgkin Study Group trials HD7 and HD10 for early-stage favorable HL and HD8 and HD11 for early-stage unfavorable HL between 1993 and 2003.
|
28418763 |
2017 |
|
Salmonella infections
|
0.020 |
GeneticVariation
|
group |
BEFREE |
In this study, we evaluate transcriptional changes in Toll-like receptors, immune/inflammatory cytokines, chemokines, antibacterial factors, and nitric oxide (NO) production in HD11 chicken macrophages in response to intracellular persistence of poultry-derived Salmonella enterica Enteritidis (SE), Typhimurium (ST), and Heidelberg (SH) that were associated with human salmonellosis.
|
28204713 |
2017 |
|
Adult Hodgkin Lymphoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Patients and Methods We analyzed updated follow-up data on 4,276 patients treated within the German Hodgkin Study Group trials HD7 and HD10 for early-stage favorable HL and HD8 and HD11 for early-stage unfavorable HL between 1993 and 2003.
|
28418763 |
2017 |
|
Childhood Hodgkin Lymphoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Patients and Methods We analyzed updated follow-up data on 4,276 patients treated within the German Hodgkin Study Group trials HD7 and HD10 for early-stage favorable HL and HD8 and HD11 for early-stage unfavorable HL between 1993 and 2003.
|
28418763 |
2017 |
|
Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
In the validation set, significantly lower levels of KAT2B (P = 0.008), HDAC11 (P = 0.009), KMT1C (P = 0.05), KDM4B (P = 0.003), KDM6B (P = 0.04), and BMI-1 (P = 0.001) transcripts were found in tumors with M3/class 2.
|
25593028 |
2015 |
|
Liver carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
The 5-HTT gene expression was almost silenced in chicken lymphoma DT40, myelomonocytic tumor HD11 and hepatoma DU249 cells, compared to their physiological counterpart.
|
26024595 |
2015 |
|
Chronic myeloproliferative disorder
|
0.020 |
Biomarker
|
disease |
BEFREE |
Using global gene expression profiling of whole blood from patients with CMPNs, we have found a pronounced deregulation of HDAC genes, involving significant up-regulation of the HDAC genes 9 and 11, with the highest expression levels being found in patients with ET (HDAC9 and 11), PMF (HDAC9) and CMPNs (both HDAC9 and HDAC11).
|
21806350 |
2012 |
|
Hodgkin Disease
|
0.020 |
Biomarker
|
disease |
BEFREE |
Pharmacologic inhibition of HDAC11 may produce a favorable antitumor immune response in patients with HL.
|
21239696 |
2011 |
|
Adult Hodgkin Lymphoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Pharmacologic inhibition of HDAC11 may produce a favorable antitumor immune response in patients with HL.
|
21239696 |
2011 |